A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10 to <18 Years) With Type 2 Diabetes Mellitus
A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10 to <18 Years) With Type 2 Diabetes Mellitus
The purpose of this study is to assess the effect of canagliflozin relative to placebo on glycated hemoglobin (HbA1c) after 26 weeks of treatment, and to assess the overall safety and tolerability of canagliflozin.
Inclusion Criteria:
Participants with a diagnosis of type 2 diabetes mellitus (T2DM)
Random C-peptide at screening greater than (>)0.6 nanogram/milliliter (ng/mL) (>0.2 nanomole/liter [nmol]/L])
HbA1c of greater than or equal to (>=)6.5 percent (%) to less than or equal to (<=)11.0% and meets 1 of the inclusion criteria below:
Exclusion Criteria:
Sacramento, California 95821, United States
Aurora, Colorado 80045, United States
Wuhan, 430030, China
Katowice, 40-752, Poland
Olsztyn, 10-561, Poland
Warsaw, 04-730, Poland
Izhevsk, 426009, Russia
Saint Petersburg, 191036, Russia
Saint Petersburg, 194100, Russia